cancer vaccines

Merck, Moderna melanoma vaccine win raises new questions

In a Phase 3 trial, a personalized mRNA cancer vaccine from Merck and Moderna cut the risk of melanoma returning or the patient dying by 42%. It is the first large randomized trial of the approach to succeed. The results…

You're all caught up

You've seen all the main stories from the past 2 days.

Moderna to present Phase 3 cancer vaccine data at ESMO

Moderna announced on Monday that late-breaking Phase 3 data for its personalized mRNA cancer therapy, intismeran autogene, will be presented at a Presidential Symposium during the European Society for Medical Oncology Congress 2026 in Madrid. The presentation is scheduled for…

Moderna eyes solo mRNA cancer vaccine, in vivo CAR-T after landmark trial

Moderna is widening its cancer drug pipeline after achieving the first positive Phase 3 result for an mRNA-based cancer treatment, a milestone the company is now leveraging to push into monotherapy vaccines, in vivo CAR-T cell therapy, and treatments targeting…